OCT 18, 2019

OPEN ACCESS

DOI:
[dx.doi.org/10.17504/protocols.io.7pwhmpe](https://doi.org/10.17504/protocols.io.7pwhmpe)

External link:
<https://doi.org/10.1371/journal.pone.0224110>

Protocol Citation: Jian-Te Lee, Ting-Yu Yen, Chun-Yi Lu, Ding-Ping Liu, Yi-Chuan Huang, Luan-Yin Chang, Li-Min Huang, Tzou-Yien Lin 2019. The EV71 neutralizing antibody test. **protocols.io** <https://dx.doi.org/10.17504/protocols.io.7pwhmpe>

MANUSCRIPT CITATION: Lee J, Yen T, Shih W, Lu C, Liu D, Huang Y, Chang L, Huang L, Lin T (2019) Enterovirus 71 seroepidemiology in Taiwan in 2017 and comparison of those rates in 1997, 1999 and 2007. PLoS ONE 14(10): e0224110. doi: [10.1371/journal.pone.0224110](https://doi.org/10.1371/journal.pone.0224110)

License: This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

The EV71 neutralizing antibody test

PLOS One

Ting-Yu
 Jian-Te Lee¹, Yen², Chun-Yi Lu², Liu^{3,4},
 Yi-Chuan Huang⁵, Luan-Yin Chang², Li-Min Huang², Tzou-Yien Lin^{6,7}

¹Department of Pediatrics, National Taiwan University Hospital, Yun-Lin Branch, Yunlin, Taiwan;

²Department of Pediatrics, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan;

³Epidemic Intelligence Center, Centers for Disease Control, Taipei, Taiwan;

⁴National Taipei University of Nursing and Health Sciences, Taipei, Taiwan;

⁵Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan;

⁶Department of Pediatrics, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan;

⁷The National Health Research Institutes, Miaoli, Taiwan.

Ai Ling Cheng

ABSTRACT

This protocol describes the process for the neutralizing antibody test of EV71.

GUIDELINES

The serum neutralizing antibody response is the major indicator of EV71 protective immunity. The neutralizing antibody test of EV71 followed the standard protocol of a neutralization test. Serum samples were heat-treated for 30 minutes at 56°C, serially diluted and mixed with 100 50% tissue culture-infective doses (TCID50) of the EV71 TW/2272/98 strain (GenBank accession number AF119795), and incubated for 2 hours at 37°C. Thereafter, rhabdomyosarcoma cells were added into each reaction well and incubated at 37°C in 5% CO₂ incubator. Each plate included a cell control, serum control, and virus back-titration. The cytopathic effect was monitored from 5 to 6days after incubation, and the serotiter was determined when the cytopathic effect was observed in one TCID50 of the virus back-titration. Seropositivity was defined as a serotiter ≥8.

Protocol status: Working

MATERIALS

Created: Sep 26, 2019

Last Modified: Oct 18, 2019

PROTOCOL integer ID:
28118

Keywords: enterovirus 71,
neutralization antibody

Serum or plasma
96 well microtiterplate
1x PBS
DMEM with 2% FBS medium
Multichannel Pipette (8 or 12)
1.5 ml eppendorf
EV71 TW/2272/98 strain (GenBank accession number AF119795)

SAFETY WARNINGS

EV71 needs to operate in BSL-2
lab

BEFORE START INSTRUCTIONS

Set water bath to 56°C
Confirm that the RD cells are healthy

1 Inactivate serum (300 µl) at 56°C for 30 min

Sample volumn (µl)	1x PBS (µl)	Dilute factor
Ex. 75	225	1:4

2 Make 2 fold serial dilution of serum from 1:4 to 1:256 with 2% FBS DMEM

sample	1-1	1-2	2-1	2-2	3-1	3-2	4-1	4-2	5-1	5-2	6-1	6-2
A 1:4	●	●	○	○	○	○	○	○	○	○	○	○
B 1:8	●	●	○	○	○	○	○	○	○	○	○	○
C 1:16	○	○	○	○	○	○	○	○	○	○	○	○
D 1:32	○	○	○	○	○	○	○	○	○	○	○	○
E 1:64	○	○	○	○	○	○	○	○	○	○	○	○
F 1:128	○	○	○	○	○	○	○	○	○	○	○	○

G 1:256	○	○	○	○	○	○	○	○	○	○	○	○
H control	●	○	○	○	○	○	○	○	○	○	○	○

- Add 50 µl 2% FBS DMEM in well B to H
- means add 50µl serum sample
- After dilution, every well has 50µl sample
- ex. sample1-1 well H: serum control; sample 1-2 well H: cell control; 1-1 and 1-2 are duplicate

- Add 50 µl of adjusted virus suspension (100TCID₅₀EV71) onto the well A to well G of microtiterplate, shake reaction well slightly
- Prepare control wells including virus control, serum control and cell control.
Virus control well : back titration from 100, 10, 1 to 1/10 100TCID₅₀
Serum control : add serum and cell only, no virus
Cell control : add cell only, no serum and no virus
- Incubate above reaction wells at 37°C for 2 hours in 5% CO₂ incubator
- Prepare RD cells suspension and adjust cell concentration to 1×10⁵/ml
- Add 100µl of adjusted RD cell into each reaction well after 2 hours in step5
- Incubate wells at 37°C in 5% CO₂ incubator for 5-6 days until virus control well reach 100TCID₅₀
- Observe CPE in each well under reverse microscope after 5-6 days incubation

- 10** Check CPE in control wells
Virus control well : 100% CPE in 100TCID₅₀ and 10TCID₅₀; 50% CPE in 1TCID₅₀, < 10% CPE in 1/10TCID₅₀
Serum control well : no CPE
Cell control well : no CPE
- 11** The NT titer was calculated as the reciprocal value of the last dilution of the antiserum that completely inhibited the CPE after incubation.
- 12** Seropositivity was defined as a reciprocal of the serotiter ≥ 8 .